FDA Grants Conditional Approval For Merck's EXZOLT CATTLE-CA1, First Topical Solution For Screwworm Prevention And Cattle Fever Tick Control

EXZOLT™ CATTLE-CA1 is the first in its class and the only product conditionally approved for both the prevention and treatment of New World screwworm and treatment and control of cattle fever tick

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) has granted a conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution). This innovative product is in the newest class of parasiticides known as isoxazolines. The pour-on solution is effective for the prevention and treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis). It is also conditionally approved for the treatment and control of cattle fever tick (Rhipicephalus microplus).